BRIEF-Moonlake Initiates Three New Clinical Trials And Expands Portfolio Of Indications For The Nanobody Sonelokimab
ReutersJan 8, 2025 12:10 PM
Jan 8 (Reuters) - MoonLake Immunotherapeutics MLTX.O:
MOONLAKE INITIATES THREE NEW CLINICAL TRIALS AND FURTHER EXPANDS THE PORTFOLIO OF INDICATIONS FOR THE NANOBODY® SONELOKIMAB
MOONLAKE IMMUNOTHERAPEUTICS - PHASE 2 AND 3 DATA READ-OUTS EXPECTED IN 2025 AND 2026
MOONLAKE IMMUNOTHERAPEUTICS - RUNNING SEVEN TRIALS IN 2025
MOONLAKE IMMUNOTHERAPEUTICS - TOPLINE PRIMARY ENDPOINT READOUT EXPECTED IN 2025
MOONLAKE IMMUNOTHERAPEUTICS - PRIMARY ENDPOINT OF S-OLARIS TRIAL IS CHANGE IN 18F-NAF UPTAKE
Source text: ID:nGNX8kGyJ9
Further company coverage: MLTX.O
((Reuters.Brief@thomsonreuters.com))
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Related Articles
What Should Stock Investors Watch in Friday’s US Jobs Report?
TradingKey - At this point in time, the stock market is obsessing over how much the US Federal Reserve (Fed) will cut interest rates in 2025.TradingKey
an hour ago
Nvidia CEO’s Remarks Hit Quantum Computing Stocks
TradingKey - Nvidia CEO Jensen Huang’s remarks on Wednesday about the technology hit stocks in the quantum computing sector. He predicted it could take decades for the technology to see widespread adoption, leading to declines in the shares of IonQ, Rigetti Computing, D-Wave Quantum, and Quantum ComTradingKey
4 hours ago
Why Did The S&P 500 And Nasdaq Composite Just Fall Over 1%?
TradingKey - The year 2025 started off on a pretty solid footing for investors with the key indices in the US – the S&P 500 Index and the tech-focused Nasdaq Composite Index – both posting gains in the first few days of trading. That followed on from some huge double-digit gains for 2023 and 2024.TradingKey
Wed, Jan 8
